SpliceBio Closes $135M Series B to Advance Gene Therapy

SpliceBio, a Catalan biotech company specializing in gene therapies using proprietary Protein Splicing technology, has secured $135 million in a Series B funding round co-led by EQT Life Sciences and Sanofi Ventures, with participation from Roche Venture Fund and existing investors. The funds will primarily support the Phase 1/2 clinical development of SB-007, an adeno-associated viral gene therapy targeting Stargardt disease, a genetic retinal disorder causing progressive vision loss and blindness for which no approved treatments currently exist. SB-007 aims to enable retinal cells to produce the full-length ABCA4 protein, addressing the underlying genetic cause regardless of the patient's specific mutation. Beyond SB-007, the financing will accelerate SpliceBio’s broader pipeline of gene therapy programs in ophthalmology, neurology, and other undisclosed indications. The investment reflects strong confidence in SpliceBio’s innovative platform, which overcomes challenges related to delivering large genes via traditional vectors, and has garnered regulatory approvals to proceed with clinical trials in both the US and the UK. New board members from EQT Life Sciences, Sanofi Ventures, and Roche Venture Fund will join SpliceBio, underscoring the strategic importance of these partnerships.